Greenland Mines Ltd

Greenland Mines Ltd develops essential medicines for chronic diseases including cancer, cardiovascular, and neurodegenerative disorders, and also engages in the development and mining of critical and precious minerals. The company operates through two main platforms: a generic drug portfolio and a biosimilar biologics platform, and a proprietary, patented gene therapy platform. The biosimilar biologics platform focuses on biologic therapies for cancer. The gene therapy platform uses a gene therapy approach to introduce a therapeutic protein called "Klotho" to treat neurodegenerative diseases. On September 12, 2022, Greenland Mines acquired five market-approved anti-cancer drugs for sale in Germany. These Market Authorizations cover four drugs used in the "FOLFOX" and "FOLFIRI" multi-drug regimens for metastatic colorectal and gastric cancer, and two drugs for metastatic lung cancer, which are important for treating various solid tumors in both childhood and adult cancers. Previously, the company acquired two off-patent bio generic antibodies from Reliance Life Sciences. In March 2026, the company completed the acquisition of Greenland Mines Corp., expanding its operations into critical and precious mineral development and mining. The company's Common Stock and Warrants trade on the Nasdaq under "GRML" and "GRMLW" respectively.